These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 7595233)

  • 41. Protective immunization against melanoma by gp100 DNA-HVJ-liposome vaccine.
    Zhou WZ; Kaneda Y; Huang S; Morishita R; Hoon D
    Gene Ther; 1999 Oct; 6(10):1768-73. PubMed ID: 10516727
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy.
    Estin CD; Stevenson US; Plowman GD; Hu SL; Sridhar P; Hellström I; Brown JP; Hellström KE
    Proc Natl Acad Sci U S A; 1988 Feb; 85(4):1052-6. PubMed ID: 3422478
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunology and immunotherapy of human malignant melanoma.
    Bystryn JC
    Dermatol Clin; 1985 Apr; 3(2):327-34. PubMed ID: 2937585
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expression of heat-stable antigen on tumor cells provides co-stimulation for tumor-specific T cell proliferation and cytotoxicity in mice.
    Wang YC; Zhu L; McHugh R; Sell KW; Selvaraj P
    Eur J Immunol; 1995 May; 25(5):1163-7. PubMed ID: 7774619
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mammalian tyrosinase-related protein-1 is recognized by autoantibodies from vitiliginous Smyth chickens. An avian model for human vitiligo.
    Austin LM; Boissy RE
    Am J Pathol; 1995 Jun; 146(6):1529-41. PubMed ID: 7778691
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Characterization of antigens reacting with vitiligo and cytoplasmic melanoma antibodies].
    Presser HJ; Morenz J; Höfs T; Zugehör M; Kühne KH; Brödemann M
    Dermatol Monatsschr; 1987; 173(8):441-5. PubMed ID: 3311840
    [No Abstract]   [Full Text] [Related]  

  • 47. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo.
    Palermo B; Campanelli R; Garbelli S; Mantovani S; Lantelme E; Brazzelli V; Ardigó M; Borroni G; Martinetti M; Badulli C; Necker A; Giachino C
    J Invest Dermatol; 2001 Aug; 117(2):326-32. PubMed ID: 11511311
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adenovirus-mediated expression of interleukin-12 induces natural killer cell activity and complements adenovirus-directed gp75 treatment of melanoma lung metastases.
    Hirschowitz EA; Crystal RG
    Am J Respir Cell Mol Biol; 1999 May; 20(5):935-41. PubMed ID: 10226063
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization.
    Surman DR; Irvine KR; Shulman EP; Allweis TM; Rosenberg SA; Restifo NP
    J Immunol Methods; 1998 May; 214(1-2):51-62. PubMed ID: 9692858
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Altered intracellular sorting signals do not influence the efficacy of genetic melanoma vaccines incorporating helper determinants in mice.
    Brück J; Steitz J; Strand D; Tüting T
    J Gene Med; 2005 May; 7(5):613-20. PubMed ID: 15580620
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In situ analysis of antigens on malignant and benign cells of the melanocyte lineage. Differential expression of two surface molecules, gp75 and p89.
    Holzmann B; Johnson JP; Kaudewitz P; Riethmüller G
    J Exp Med; 1985 Feb; 161(2):366-77. PubMed ID: 3973533
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detection of serum anti-melanocyte antibodies and identification of related antigens in patients with vitiligo.
    Zhu MC; Liu CG; Wang DX; Zhan Z
    Genet Mol Res; 2015 Dec; 14(4):16060-73. PubMed ID: 26662399
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development.
    Chen YT; Stockert E; Tsang S; Coplan KA; Old LJ
    Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8125-9. PubMed ID: 7667256
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Autonomous histopathological regression of primary tumours associated with specific immune responses to cancer antigens.
    Saleh FH; Crotty KA; Hersey P; Menzies SW; Rahman W
    J Pathol; 2003 Jul; 200(3):383-95. PubMed ID: 12845635
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient.
    Mantovani S; Garbelli S; Palermo B; Campanelli R; Brazzelli V; Borroni G; Martinetti M; Benvenuto F; Merlini G; della Cuna GR; Rivoltini L; Giachino C
    J Invest Dermatol; 2003 Aug; 121(2):308-14. PubMed ID: 12880423
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response.
    Cavallo F; Martin-Fontecha A; Bellone M; Heltai S; Gatti E; Tornaghi P; Freschi M; Forni G; Dellabona P; Casorati G
    Eur J Immunol; 1995 May; 25(5):1154-62. PubMed ID: 7539748
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serological characterization of a shared melanoma-associated antigen of mouse melanomas: relationship to the B700 glycoprotein.
    DeLeo AB; Hearing VJ; Vieira WD; Law LW
    Melanoma Res; 1991; 1(2):133-40. PubMed ID: 1668533
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo.
    Trcka J; Moroi Y; Clynes RA; Goldberg SM; Bergtold A; Perales MA; Ma M; Ferrone CR; Carroll MC; Ravetch JV; Houghton AN
    Immunity; 2002 Jun; 16(6):861-8. PubMed ID: 12121667
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
    Boukerche H; Baril P; Tabone E; Bérard F; Sanhadji K; Balme B; Wolf F; Perrot H; Thomas L
    Cancer Res; 2000 Oct; 60(20):5848-56. PubMed ID: 11059782
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.
    Kohlmeyer J; Cron M; Landsberg J; Bald T; Renn M; Mikus S; Bondong S; Wikasari D; Gaffal E; Hartmann G; Tüting T
    Cancer Res; 2009 Aug; 69(15):6265-74. PubMed ID: 19622767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.